The approval was based on data from the single-arm, open-label phase 2 KOMET-001 trial, which evaluated ziftomenib, a menin inhibitor, in adults with R/R AML with an NPM1 mutation.
The ongoing dispute between Ben Shapiro and Tucker Carlson took center stage on Thursday during the opening night of Turning Point USA’s AmericaFest, the organization’s annual gathering and its first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback